Clinical utility of noninvasive imaging in patients with suspected transthyretin amyloid cardiomyopathy: a multicenter registry

Clinical utility of noninvasive imaging in patients with suspected transthyretin amyloid cardiomyopathy: a multicenter registry - Clinical utility of noninvasive imaging in patients with suspected ATTR-CM: a multicenter registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056610

Enrollment

5000

Registered

2024-12-31

Start date

2025-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transthyretin amyloid cardiomyopathy (ATTR-CM)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with suspected ATTR-CM who underwent 99mTc-pyrophosphate scintigraphy between January 1, 2010, and September 30, 2024 (regardless of age)

Exclusion criteria

Exclusion criteria: 1) Cases in which the image evaluation using 99mTc-pyrophosphate scintigraphy is difficult. 2) Patients who are judged as ineligible for this study by the research director.

Design outcomes

Primary

Measure	Time frame
Differences in the degrees of 99mTc-pyrophosphate uptakes and the diagnosis rate of ATTR-CM among the different categories of patients with suspected ATTR-CM (i.e., age, sex, and LVEF [<40%, 40-50%, and >50%]).	—

Secondary

Measure	Time frame
1) To assess the association between the degrees of 99mTc-pyrophosphate uptakes, all-cause death, and clinical events. 2) To assess the clinical validity of Kumamoto Criteria and Mayo Simple Score for the prediction of 99mTc-pyrophosphate uptakes and the diagnosis of ATTR-CM. 3) To develop novel clinical scores for the prediction of 99mTc-pyrophosphate uptakes and the diagnosis of ATTR-CM. 4) To assess the association between the degrees of 99mTc-pyrophosphate uptakes and the diagnosis rate of non-ATTR-CM cardiomyopathies.	—

Measure

Time frame

1) To assess the association between the degrees of 99mTc-pyrophosphate uptakes, all-cause death, and clinical events. 2) To assess the clinical validity of Kumamoto Criteria and Mayo Simple Score for the prediction of 99mTc-pyrophosphate uptakes and the diagnosis of ATTR-CM. 3) To develop novel clinical scores for the prediction of 99mTc-pyrophosphate uptakes and the diagnosis of ATTR-CM. 4) To assess the association between the degrees of 99mTc-pyrophosphate uptakes and the diagnosis rate of non-ATTR-CM cardiomyopathies.

—

Countries

Japan

Contacts

Public ContactTadao Aikawa

Juntendo University Hospital Department of Cardiovascular Biology and Medicine

tadao.aikawa@juntendo.ac.jp03-3813-3111

Outcome results